New study links Dopamine to Autism symptoms
Researchers at Karolinska Institutet have uncovered new insights into the mechanisms underlying autism spectrum disorder (ASD). The study, recently published in Cell Reports, explores how changes in dopamine (DA) neurotransmission in the brain contribute to the behavioural symptoms of Autism.
Autism is diagnosed based on behaviours that vary greatly between individuals, often overlapping with other conditions, making accurate diagnosis challenging. The study focuses on a mouse model of ASD with elevated levels of eukaryotic initiation factor 4E (eIF4E), a protein that plays a crucial role in the process of translating genetic information into proteins.
“Our study shows that mice with an autism-risk gene, eIF4E, have reduced release of dopamine, a chemical messenger (or neurotransmitter) that is important for motivation, learning and movement,” says Emanuela Santini, principal researcher at the department of neuroscience and last author of the article.
Using state-of-the-art techniques like optogenetics, which uses light to control specific brain circuit, the researchers traced the problem to reduced activation of nicotinic receptors by acetylcholine, another neurotransmitter important for decision-making.
The study helps to explain the neurobiological basis for behavioural inflexibility, a common challenge in autism.
Why are the results important?
Understanding how brain circuits and neuronal communication are altered in autism is crucial.
“Our findings reveal that the basal ganglia—a brain circuit regulating adaptive behaviour and motor functions—is affected in autism, with disruptions in how dopamine and acetylcholine work together”, says Emanuela Santini.
These findings provide insight into the brain mechanisms behind behavioural inflexibility in autism, potentially aiding future diagnostic approaches.
Comprehensive approach
The researchers used a comprehensive approach, combining genetics, behavioural analysis, synaptic physiology, and imaging techniques. They measured dopamine release in mice with mutation in the eIF4E gene, which is important for making new proteins. Mutations in this gene have been linked to autism in patients. These mice have autism-like behaviours, such as difficulty adapting to change, repetitive actions, and social challenges, making them a valuable model for studying autism.
“We used optogenetics to understand why dopamine release was reduced in ASD mice. We activated dopamine or acetylcholine neurons and found that dopamine release triggered by acetylcholine neurons was reduced”, explains Anders Borgkvist, principal researcher at the same department and co-author of the study.
The team then used imaging techniques to measure acetylcholine levels and calcium influx. Calcium is essential for neurotransmitter release. In the eIF4E mice, acetylcholine binding to dopamine axons was impaired, leading to less calcium influx. Increasing calcium restored dopamine release, showing that the problem lies in nicotinic receptor function.
The next step
“Our findings suggest that behavioural inflexibility in autism arises from deficits in the communication between dopamine and acetylcholine in the basal ganglia. We will continue to investigate how this affects other parts of the brain”, says Anders Borgkvist.
“This not only enhances our understanding of ASD but also paves the way for innovative therapeutic approaches that could significantly improve the lives of those affected by the disorder”, adds Emanuela Santini.
The study, performed at Karolinska, also involved researchers from Columbia University, University of California San Francisco in the US. It was mainly funded by the Swedish Research Council, Knut and Alice Wallenberg Foundation, Olle Engkvists Stiftelse and StratNeuro at Karolinska Institutet.
Publication
Dysregulated acetylcholine-mediated dopamine neurotransmission in the eIF4E Tg mouse model of autism spectrum disorders.
Carbonell-Roig J, Aaltonen A, Wilson K, Molinari M, Cartocci V, McGuirt A, Mosharov E, Kehr J, Lieberman OJ, Sulzer D, Borgkvist A, Santini E
Cell Rep 2024 Dec;43(12):114997